Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 2
1978 2
1979 4
1980 8
1981 6
1982 8
1983 15
1984 11
1985 13
1986 11
1987 6
1988 11
1989 13
1990 22
1991 14
1992 15
1993 10
1994 22
1995 12
1996 24
1997 26
1998 36
1999 24
2000 42
2001 33
2002 34
2003 34
2004 26
2005 22
2006 20
2007 15
2008 27
2009 29
2010 26
2011 21
2012 23
2013 24
2014 19
2015 20
2016 14
2017 16
2018 31
2019 38
2020 42
2021 31
2022 27
2023 15
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 14679153

885 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG); Castiglione-Gertsch M, O'Neill A, Price KN, Goldhirsch A, Coates AS, Colleoni M, Nasi ML, Bonetti M, Gelber RD. International Breast Cancer Study Group (IBCSG), et al. J Natl Cancer Inst. 2003 Dec 17;95(24):1833-46. doi: 10.1093/jnci/djg119. J Natl Cancer Inst. 2003. PMID: 14679153 Clinical Trial.
Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.
Karlsson P, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Collins J, Murray E, Zaman K, Colleoni M, Gusterson BA, Viale G, Regan MM, Coates AS, Goldhirsch A. Karlsson P, et al. Ann Oncol. 2011 Oct;22(10):2216-26. doi: 10.1093/annonc/mdq735. Epub 2011 Feb 16. Ann Oncol. 2011. PMID: 21325445 Free PMC article. Clinical Trial.
Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
Bernhard J, Zahrieh D, Castiglione-Gertsch M, Hürny C, Gelber RD, Forbes JF, Murray E, Collins J, Aebi S, Thürlimann B, Price KN, Goldhirsch A, Coates AS; International Breast Cancer Study Group Trial VIII. Bernhard J, et al. J Clin Oncol. 2007 Jan 20;25(3):263-70. doi: 10.1200/JCO.2005.04.5393. Epub 2006 Dec 11. J Clin Oncol. 2007. PMID: 17159194 Clinical Trial.
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B; Zoladex Early Breast Cancer Research Association Study. Jonat W, et al. J Clin Oncol. 2002 Dec 15;20(24):4628-35. doi: 10.1200/JCO.2002.05.042. J Clin Oncol. 2002. PMID: 12488406
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS. Viale G, et al. J Clin Oncol. 2008 Mar 20;26(9):1404-10. doi: 10.1200/JCO.2007.10.6393. J Clin Oncol. 2008. PMID: 18349391 Clinical Trial.
Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it.
Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Romeo D, Sismondi P, Giai M, Genta F, Pacini P, Distante V, Bolognesi A, Aldrighetti D, Farris A. Boccardo F, et al. J Clin Oncol. 2000 Jul;18(14):2718-27. doi: 10.1200/JCO.2000.18.14.2718. J Clin Oncol. 2000. PMID: 10894871 Clinical Trial.
885 results